Deleterious role of TNF-α in retinal ischemia-reperfusion injury
Deleterious role of TNF-α in retinal ischemia-reperfusion injury
复制标题
DOI:
10.1167/iovs.07-0817
复制
发表时间:
2008-08-01
影响因子:
4.4
通讯作者:
Rosenbaum, Daniel M.
中科院分区:
文献类型:
--
作者:
Berger, Samuel;Savitz, Sean I.;Rosenbaum, Daniel M.
PURPOSE. Tumor necrosis factor (TNF)-alpha is a mediator of neuronal cell death and survival in ischemia-reperfusion injury. This study was conducted to further elucidate the role of TNF-alpha and its receptor in an in vivo model of retinal ischemia reperfusion injury by investigating its effects on retinal histopathology and function.METHODS. Retinal ischemia-reperfusion injury was performed on p55 and p75 knockout (KO) mice and Sprague-Dawley rats using the high intraocular pressure method. The temporal expression of TNF-alpha was ascertained with immunohistochemical staining. Separate rats received intravitreal recombinant TNF-alpha or neutralizing antibody before or after ischemia. TUNEL labeling was performed to assess for cell death, and electroretinography was performed to assess function.RESULTS. TNF-alpha expression peaked at 12 to 24 hours after ischemia-reperfusion injury. TUNEL staining was diminished after intravitreal TNF-alpha antibody. Both transgenic KOs demonstrated significantly less functional impairment. Rats receiving recombinant TNF-alpha 48 hours after ischemia showed exaggerated functional impairment. Animals treated with TNF-alpha antibody before ischemia displayed significant functional improvement.CONCLUSIONS. TNF-alpha plays a largely deleterious role in ischemia -reperfusion injury in an in vivo model of retinal injury. Direct neutralization of this cytokine partially preserves retinal function. The diverse characteristics of TNF-alpha are attributed in part to the timing of its expression after injury. TNF-alpha receptor expression and function, along with combination treatments targeting death receptor-mediated apoptosis, should be further explored to develop neuroprotective therapeutic strategies for acute retinal ischemic disorders.